The significant elevation of IP-10 in the sera and tissue of LS patients with active versus inactive disease, along with correlations between IP-10 levels and standardized disease outcome measures of activity in LS, strongly suggest that IP-10 may be a biomarker for disease activity in LS. This evidence concerns the gene CXCL10 and Leigh syndrome.